Live data · NADAC + Part D CY24 · reviewed daily

Secukinumab (COSENTYX)

Interleukin-17A Antagonist class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2015-01-21
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$2.59B in CY2024 Part D spend290K claims · 55K beneficiaries · 329 plans surveyed

Lowest NADAC
$3924.35/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$5539.28
Across all dosage forms in distribution.
Highest NADAC
$7879.81
Range is tight.
Plans with PA
1032 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Secukinumab used for?

Secukinumab is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Secukinumab?

No. Secukinumab is brand-only with no generic equivalents currently in market.

How much does my plan pay for Secukinumab?

Across 329 Part D plans, Secukinumab averages $5539.28/unit (NADAC). Lowest available: $3924.35/unit. Highest in distribution: $7879.81/unit.

Is Secukinumab on the FDA shortage list?

No. Secukinumab is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.